Friday, January 31, 2014

NCC Q4 and Full Year Report 2013

NCC REPORTS FOURTH-QUARTER AND FULL-YEAR 2013 RESULTS

October 1 – December 31, 2013

  • Orders received: SEK 14,363 M (15,423)
  • Net sales SEK 21,073 M (19,069)
  • Profit after financial items SEK 1,472 M (1,258)
  • Profit after tax for the period SEK 1,231 M (1,130)
  • Earnings per share: SEK 11,39 (10.43)

January 1 – December 31, 2013

  • Orders received: SEK 56,979 M (55,759)
  • Net sales: SEK 57,823 M (57,227)
  • Profit after financial items SEK 2,400 M (2,277)
  • Profit after tax for the period SEK 1,989 M (1,910)
  • Earnings per share: SEK 18.40 (17.62)
  • The Board of Directors proposes a dividend for 2013 of SEK 12.00 (10.00) per share, divided between two payment occasions



For more information, click the link below
NCC Q4-2013

Thursday, January 30, 2014

Altria Q4 and Full Year Report 2013

ALTRIA REPORTS FOURTH-QUARTER AND FULL-YEAR 2013 RESULTS;
OUTLOOK FOR 2014 

  • Altria’s 2013 fourth-quarter reported diluted earnings per share (EPS) decreased 56.4% to $0.24, as comparisons were affected by special items.
  • Altria’s 2013 fourth-quarter adjusted diluted EPS, which excludes the impact of special items, increased 3.6% to $0.57.
  • Altria’s 2013 full-year reported diluted EPS increased 9.7% to $2.26, as comparisons were affected by special items.
  • Altria’s 2013 full-year adjusted diluted EPS, which excludes the impact of special items, grew 7.7% to $2.38.
  • Altria forecasts its 2014 full-year reported diluted EPS to be in the range of $2.51 to $2.58, and 2014 full-year adjusted diluted EPS to be in the range of $2.52 to $2.59, representing a growth rate of 6% to 9% from an adjusted diluted EPS base of $2.38 in 2013.


For more information, click the link below
Altria Q4-2013

UPM Q4 and Full Year Report 2013

UPM REPORTS FOURTH-QUARTER AND FULL-YEAR 2013 RESULTS;
OUTLOOK FOR 2014 

Q4/2013 (compared with Q4/2012) 

  • Earnings per share excluding special items were EUR 0.27 (0.20), and reported EUR 0.06 (-2.83).
  • Operating profit excluding special items was EUR 207 million, 8.0% of sales (146 million, 5.5% of sales).
  • EBITDA was EUR 302 million, 11.7% of sales (317 million, 11.9% of sales).
  • 48% of the targeted annualised EUR 200 million cost savings achieved in Q4/201.
  • Operating cash flow was EUR 262 million, net debt decreased to EUR 3,040 million.

Full year 2013 (compared with 2012) 

  • Earnings per share excluding special items were EUR 0.91 (0.74), and reported EUR 0.63 (-2.14).
  • Operating profit excluding special items was EUR 683 million, 6.8% of sales (556 million, 5.3% of sales).
  • EBITDA was EUR 1,155 million, 11.5% of sales (1,312 million, 12.5% of sales).
  • UPM introduced a new business structure and is implementing a profit improvement programme and focused growth initiatives.
  • Board’s proposal for dividend per share EUR 0.60 (0.60).

 

Outlook for 2014

  • Growth in the European economy is expected to remain low in 2014, but improve from last year. Growth in the US and in the developing economies is expected to continue to outperform Europe.
  • UPM’s business outlook for H1 2014 is broadly stable.
  • In H1 2014, UPM’s performance is expected to be underpinned by stable overall outlook for UPM Energy, UPM Raflatac, UPM Paper Asia and UPM Plywood, as compared to H2 2013.


For more information, click the link below
UPM Q4-2013


 

TeliaSonera Q4 and Full Year Report 2013

TELIASONERA REPORTS FOURTH-QUARTER AND FULL-YEAR 2013 RESULTS;
OUTLOOK FOR 2014

Fourth quarter summary

  • Net sales in local currencies, excluding acquisitions and disposals, decreased 0.2
    percent. In reported currency, net sales decreased 2.1 percent to SEK 26,503 mil-
    lion (27,069).
  • The addressable cost base in local currencies, excluding acquisitions and dis-posals, increased 2.8 percent. In reported currency, the addressable cost base increased 1.0 percent to SEK 7,466 million (7,394).
  • EBITDA, excluding non-recurring items, increased 0.1 percent in local currencies, excluding acquisitions and disposals. In reported currency, EBITDA, excluding non-recurring items, decreased 3.0 percent to SEK 8,728 million (9,002). The EBITDA margin, excluding non-recurring items, decreased to 32.9 percent (33.3).
  • Operating income, excluding non-recurring items, decreased 7.0 percent to SEK 7,100 million (7,636). Operating income decreased to SEK 4,560 million (7,826).
  • Net income attributable to owners of the parent company decreased 68.2 percent to SEK 2,190 million (6,880). Earnings per share decreased to SEK 0.51 (1.59).
  • Free cash flow was SEK 2,126 million (2,934).

Full year summary

  • Net sales in local currencies, excluding acquisitions and disposals, decreased 0.2 percent. In reported currency, net sales decreased 3.0 percent to SEK 101,700 million (104,898).
  • Net income attributable to owners of the parent company decreased 24.7 percent to SEK 14,970 million (19,886) and earnings per share decreased to SEK 3.46 (4.59).
  • Free cash flow was SEK 16,310 million (23,740). Free cash flow excluding divi-dends from MegaFon was SEK 14,370 million (12,014).
  • The Board of Directors proposes an ordinary dividend of SEK 3.00 per share (2.85), totaling SEK 13.0 billion (12.3) or 87 percent (62) of net income attributable to owners of the parent company.

Outlook for 2014

  • Net sales in local currencies, excluding acquisitions and disposals, are expected to be around the same level as in 2013. Currency fluctuations may have a material impact on reported figures in Swedish krona.
  • The EBITDA margin, excluding non-recurring items, is expected to be around the same level as in 2013 (35.0 percent).
  • The CAPEX-to-sales ratio is expected to be approximately 15 percent, excluding license and spectrum fees.

For more information, click the link below
TeliaSonera Q4-2013

 

Wednesday, January 29, 2014

AT&T Q4 and Full Year Report 2013

AT&T REPORTS FOURTH-QUARTER AND FULL-YEAR 2013 RESULTS;
OUTLOOK FOR 2014

  • Fourth-quarter consolidated revenues of $33.2 billion, up 1.8 percent versus the year-earlier period, For full year 2013, compared with 2012 results, AT&T's consolidated revenues totaled $128.8 billion versus $127.4 billion.
  • $1.31 diluted EPS in the fourth quarter compared to $(0.68) diluted EPS in the year-ago period. Excluding significant items, EPS was $0.53 versus $0.44, up 20.5 percent year over year. For full year 2013,  earnings per share totaled $2.50, compared with $2.31.
  • More than 2 million new wireless and wireline high speed broadband connections added in the fourth quarter.
  • Nearly $23 billion returned to shareowners in 2013 through dividends and share repurchases.

Outlook:

  • In 2014, AT&T expects continued consolidated revenue growth in the 2 to 3 percent range.
  • AT&T expects capital expenditures in the $21 billion range. 
  • Free cash flow is expected to be in the $11 billion range.


For more information, click the link below
AT&T Q4-2013

Tuesday, January 28, 2014

Pfizer Q4 and Full Year Report 2013

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2013 RESULTS;
PROVIDES 2014 FINANCIAL GUIDANCE

  • Fourth-Quarter 2013 Reported Revenues of $13.6 Billion (13.9), Full-Year 2013 Reported Revenues of $51.6 Billion (54.7).
  • Fourth-Quarter 2013 Adjusted Diluted EPS of $0.56 (0.46), Reported Diluted EPS of $0.39 (0.89), Full-Year 2013 Adjusted Diluted EPS of $2.22 (2.10), Reported Diluted EPS(1) of $3.19 (1.94).
  • Repurchased $4.6 Billion and $16.3 Billion of Common Stock in Fourth-Quarter and Full-Year 2013, Respectively; Returned Approximately $23 Billion to Shareholders Through Share Repurchases and Dividends in 2013.

Pfizer's 2014 financial guidance:

  • Adjusted Revenues: $49.2 to $51.2 billion
  • Reported Diluted EPS: $1.57 to $1.72
  • Adjusted Diluted EPS: $2.20 to $2.30


For more information, click the link below
Pfizer Q4-2013

Sunday, January 19, 2014

Intel Q4 and Full Year Report 2013

Intel Reports Full-Year Revenue of $52.7 Billion, Net Income of $9.6 Billion
Generates $21 Billion in Cash from Operations

 

  • Operating income of $3.5 billion, up 12 percent year-over-year
  • EPS of 51 cents, up 6 percent year-over-year
  • PC Client Group revenue of $8.6 billion, flat year-over-year
  • Data Center Group revenue of $3.0 billion, up 8 percent year-over-year









 For more information, click the link below

Intel Q4-2013 

Saturday, January 18, 2014

Recent Buy Philip Morris International Inc. PM

17th January 2014 I Bought 85 shares of PM at $83.49 per share plus commission.

Philip Morris International Inc. (PMI) is a holding company. PMI’s subsidiaries and affiliates and their licensees are engaged in the manufacture and sale of cigarettes and other tobacco products in markets outside of the United States of America. Its products are sold in approximately 180 countries. The Company divides its markets into four geographic segments: The European Union (EU) Region , The Eastern Europe, Middle East & Africa (EEMA) Region , The Asia Region and The Latin America & Canada Region.

Saturday, January 11, 2014

GlaxoSmithKline plc Dividend Stock Analysis

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also produces paediatric and adult vaccines to prevent a range of infectious diseases, including hepatitis A and B; diphtheria, tetanus, and whooping cough; measles, mumps, and rubella; polio; typhoid; influenza; and bacterial meningitis. In addition, it provides consumer health products in oral care, nutritional, total wellness, and skin health areas. The company's total wellness

You might also like